BioCentury
ARTICLE | Company News

Kode Biotech, Agalimmune deal

July 13, 2015 7:00 AM UTC

Kode granted Agalimmune exclusive rights to use Function-Spacer-Lipid (FSL) cell surface membrane technology in the field of intratumoral injection to treat cancer. Kode is eligible to receive up to $...